On October 14, 2020, the U.S. Environmental Protection Agency (EPA) released a much-anticipated draft guidance that is intended to help companies demonstrate to EPA that their products have “long-lasting” or “residual” effectiveness on surfaces against viruses like SARS-CoV-2, the coronavirus that causes COVID-19.  EPA has not before now provided guidance on how stakeholders can demonstrate to EPA’s satisfaction that their product remains efficacious for periods of time given the broad diversity of contact opportunities and scenarios, which is why this guidance is so significant.  Pursuant to Title VII of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, EPA intends to expedite reviews for addition of residual (i.e., extended or long-lasting) efficacy claims for currently registered products or new product registrations that are listed on EPA’s Disinfectant List N, that would qualify for List N, or products that can be used as a residual supplement to disinfectants on List N.  For more information on this important guidance document, please read the full memorandum.

Read more >> https://www.lawbc.com/regulatory-developments/entry/epa-provides-expedited-pathway-for-companies-to-claim-long-lasting-efficacy